Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890175535> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W2890175535 abstract "TPS2617 Background: The 90kDa heat shock chaperone protein (HSP90) exerts housekeeping functions within cells. HSP90 participates in the folding, stabilization, activation, and proteolytic turnover of mutant or over-expressed “client proteins” that contribute to the growth and survival of cancer cells. HSP90 inhibition leads to degradation of these aberrant proteins through the ubiquitin-proteasome pathway, allowing for simultaneous targeting of multiple pathways. Inhibition of HSP90 alone stimulates a compensatory upregulation of HSP70, which is anti-apoptotic at the pre-mitochondrial, mitochondrial and post-mitochondrial levels. The transcriptional induction of HSP70 has been linked to the activity of CDK9. In vitro and in vivo studies show that disruption of HSP70 induction by CDK9 inhibition can augment HSP90 inhibitor responses. Combined inhibition of HSP90 and CDK9 may produce synergistic anti-tumor activity. Methods: We are conducting an a phase I trial of the combination of the HSP90 inhibitor onalespib, and the CDK9 inhibitor AT7519, utilizing a 3+3 trial design, with dose-limiting toxicities defined during cycle 1. Estimated enrollment: 37 patients. Onalespib and AT7519M are both administered on days 1, 4, 8, and 11 of a 21-day cycle following a 1-week lead-in of onalespib alone to facilitate PK/PD endpoints. Patients must have histologically confirmed solid tumors that have progressed on standard of care therapy or for which no standard treatment exists, with an ECOG 0-1. Exclusion criteria include a prolonged QTc interval (Fridericia formula), pre-existing retinal disease, or cardiac dysfunction with EF < 50% at study entry. Current pharmacodynamic analyses include the analysis of HSP70 expression in plasma and peripheral blood mononuclear cells after treatment with onalespib, and after the combination, as proof-of-principle of target inhibition. At this time, DL1 has completed enrollment; accrual is ongoing with measurement of HSP90 client proteins and HSP70 levels in patient plasma and PBMC samples. This trial is open through the ETCTN. Clinical trial information: NCT02503709." @default.
- W2890175535 created "2018-09-27" @default.
- W2890175535 creator A5000193426 @default.
- W2890175535 creator A5003245399 @default.
- W2890175535 creator A5013091949 @default.
- W2890175535 creator A5017244775 @default.
- W2890175535 creator A5017421409 @default.
- W2890175535 creator A5036678244 @default.
- W2890175535 creator A5040289016 @default.
- W2890175535 creator A5041064192 @default.
- W2890175535 creator A5041200743 @default.
- W2890175535 creator A5045409088 @default.
- W2890175535 creator A5045419282 @default.
- W2890175535 creator A5050224107 @default.
- W2890175535 creator A5059433745 @default.
- W2890175535 creator A5080736692 @default.
- W2890175535 creator A5088227922 @default.
- W2890175535 creator A5088474933 @default.
- W2890175535 creator A5089357607 @default.
- W2890175535 creator A5089509810 @default.
- W2890175535 date "2017-05-20" @default.
- W2890175535 modified "2023-10-02" @default.
- W2890175535 title "Phase 1 study of onalespib, HSP90 inhibitor, and AT7519M, CDK9 inhibitor, in patients with advanced solid tumors." @default.
- W2890175535 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.tps2617" @default.
- W2890175535 hasPublicationYear "2017" @default.
- W2890175535 type Work @default.
- W2890175535 sameAs 2890175535 @default.
- W2890175535 citedByCount "1" @default.
- W2890175535 countsByYear W28901755352021 @default.
- W2890175535 crossrefType "journal-article" @default.
- W2890175535 hasAuthorship W2890175535A5000193426 @default.
- W2890175535 hasAuthorship W2890175535A5003245399 @default.
- W2890175535 hasAuthorship W2890175535A5013091949 @default.
- W2890175535 hasAuthorship W2890175535A5017244775 @default.
- W2890175535 hasAuthorship W2890175535A5017421409 @default.
- W2890175535 hasAuthorship W2890175535A5036678244 @default.
- W2890175535 hasAuthorship W2890175535A5040289016 @default.
- W2890175535 hasAuthorship W2890175535A5041064192 @default.
- W2890175535 hasAuthorship W2890175535A5041200743 @default.
- W2890175535 hasAuthorship W2890175535A5045409088 @default.
- W2890175535 hasAuthorship W2890175535A5045419282 @default.
- W2890175535 hasAuthorship W2890175535A5050224107 @default.
- W2890175535 hasAuthorship W2890175535A5059433745 @default.
- W2890175535 hasAuthorship W2890175535A5080736692 @default.
- W2890175535 hasAuthorship W2890175535A5088227922 @default.
- W2890175535 hasAuthorship W2890175535A5088474933 @default.
- W2890175535 hasAuthorship W2890175535A5089357607 @default.
- W2890175535 hasAuthorship W2890175535A5089509810 @default.
- W2890175535 hasConcept C104317684 @default.
- W2890175535 hasConcept C126322002 @default.
- W2890175535 hasConcept C181199279 @default.
- W2890175535 hasConcept C185592680 @default.
- W2890175535 hasConcept C205260736 @default.
- W2890175535 hasConcept C2775932338 @default.
- W2890175535 hasConcept C2777560012 @default.
- W2890175535 hasConcept C3018687534 @default.
- W2890175535 hasConcept C502942594 @default.
- W2890175535 hasConcept C55493867 @default.
- W2890175535 hasConcept C71924100 @default.
- W2890175535 hasConceptScore W2890175535C104317684 @default.
- W2890175535 hasConceptScore W2890175535C126322002 @default.
- W2890175535 hasConceptScore W2890175535C181199279 @default.
- W2890175535 hasConceptScore W2890175535C185592680 @default.
- W2890175535 hasConceptScore W2890175535C205260736 @default.
- W2890175535 hasConceptScore W2890175535C2775932338 @default.
- W2890175535 hasConceptScore W2890175535C2777560012 @default.
- W2890175535 hasConceptScore W2890175535C3018687534 @default.
- W2890175535 hasConceptScore W2890175535C502942594 @default.
- W2890175535 hasConceptScore W2890175535C55493867 @default.
- W2890175535 hasConceptScore W2890175535C71924100 @default.
- W2890175535 hasLocation W28901755351 @default.
- W2890175535 hasOpenAccess W2890175535 @default.
- W2890175535 hasPrimaryLocation W28901755351 @default.
- W2890175535 hasRelatedWork W2000889104 @default.
- W2890175535 hasRelatedWork W2004798728 @default.
- W2890175535 hasRelatedWork W2011038682 @default.
- W2890175535 hasRelatedWork W2035896591 @default.
- W2890175535 hasRelatedWork W2056788983 @default.
- W2890175535 hasRelatedWork W2080409112 @default.
- W2890175535 hasRelatedWork W2165271759 @default.
- W2890175535 hasRelatedWork W2168844771 @default.
- W2890175535 hasRelatedWork W2219983012 @default.
- W2890175535 hasRelatedWork W2263350340 @default.
- W2890175535 hasRelatedWork W2334168507 @default.
- W2890175535 hasRelatedWork W2624719401 @default.
- W2890175535 hasRelatedWork W2770953751 @default.
- W2890175535 hasRelatedWork W2810620131 @default.
- W2890175535 hasRelatedWork W2945149863 @default.
- W2890175535 hasRelatedWork W2977382041 @default.
- W2890175535 hasRelatedWork W3003697743 @default.
- W2890175535 hasRelatedWork W3134463956 @default.
- W2890175535 hasRelatedWork W1583597506 @default.
- W2890175535 hasRelatedWork W2824858060 @default.
- W2890175535 isParatext "false" @default.
- W2890175535 isRetracted "false" @default.
- W2890175535 magId "2890175535" @default.
- W2890175535 workType "article" @default.